Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 4-amino-n-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide
2. Amisulpride
3. Barnetil
4. Dan 2163
5. Dan-2163
6. Lin 1418
7. Lin-1418
8. N-(ethyl-1-pyrrolidinyl- 2-methyl)methoxy-2-ethylsulfonyl-5-benzamide
9. Solian
10. Sultopride Hydrochloride
1. 53583-79-2
2. Barnetil
3. Topral
4. Lin 1418
5. Sultopridum [inn-latin]
6. Lin-1418
7. Aa0g3tw31w
8. Chebi:9356
9. N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-o-anisamide
10. Sultopride (inn)
11. Barnotil
12. Benzamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxy-
13. Sultopride [inn]
14. Sultopridum
15. Sultroprida
16. Sultopride [inn:dcf]
17. N-((1-ethylpyrrolidin-2-yl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide
18. N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxy-benzamide
19. Sultroprida [inn-spanish]
20. (+/-)-sultopride
21. Ncgc00185771-01
22. Einecs 258-641-9
23. Unii-aa0g3tw31w
24. Brn 0494772
25. Sultopride [mi]
26. Sultopride [who-dd]
27. 5-22-08-00103 (beilstein Handbook Reference)
28. Schembl149197
29. Chembl277945
30. Dtxsid9023627
31. Bdbm86720
32. Nsc_5357
33. N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide
34. Pdsp1_001575
35. Pdsp2_001559
36. Akos024255726
37. O-anisamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-
38. Db13273
39. Ks-5337
40. Hy-42849
41. Cas_53583-79-2
42. Db-071706
43. Cs-0040602
44. Ft-0725190
45. D08549
46. L001065
47. Q4445779
48. (+/-)-n-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide
49. N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide
50. N-[(1-ethylpyrrolidin-2-yl)methyl]-5-(ethylsulfonyl)-2-(methyloxy)benzamide
| Molecular Weight | 354.5 g/mol |
|---|---|
| Molecular Formula | C17H26N2O4S |
| XLogP3 | 1.6 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 7 |
| Exact Mass | 354.16132849 g/mol |
| Monoisotopic Mass | 354.16132849 g/mol |
| Topological Polar Surface Area | 84.1 Ų |
| Heavy Atom Count | 24 |
| Formal Charge | 0 |
| Complexity | 517 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Antidepressive Agents, Second-Generation
A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake. (See all compounds classified as Antidepressive Agents, Second-Generation.)
Antipsychotic Agents
Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)
Dopamine Antagonists
Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)
N - Nervous system
N05 - Psycholeptics
N05A - Antipsychotics
N05AL - Benzamides
N05AL02 - Sultopride
FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
ABOUT THIS PAGE
A Sultopride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Sultopride, including repackagers and relabelers. The FDA regulates Sultopride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Sultopride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Sultopride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Sultopride supplier is an individual or a company that provides Sultopride active pharmaceutical ingredient (API) or Sultopride finished formulations upon request. The Sultopride suppliers may include Sultopride API manufacturers, exporters, distributors and traders.
click here to find a list of Sultopride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Sultopride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Sultopride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Sultopride GMP manufacturer or Sultopride GMP API supplier for your needs.
A Sultopride CoA (Certificate of Analysis) is a formal document that attests to Sultopride's compliance with Sultopride specifications and serves as a tool for batch-level quality control.
Sultopride CoA mostly includes findings from lab analyses of a specific batch. For each Sultopride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Sultopride may be tested according to a variety of international standards, such as European Pharmacopoeia (Sultopride EP), Sultopride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Sultopride USP).
LOOKING FOR A SUPPLIER?
